Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 _________________________________________ Commission File Number 001-03157 INTERNATIONAL PAPER COMPANY (Exact name of registrant as specified in it ...

Financial Performance - Total revenues for the three months ended September 30, 2025, were $311,455 thousand, slightly up from $309,588 thousand in the same period of 2024, reflecting a 0.6% increase[17]. - Net income for the three months ended September 30, 2025, was $163,497 thousand, down from $180,669 thousand in 2024, indicating a decrease of 9.5%[19]. - The company reported a total comprehensive income of $226,054 thousand for the three months ended September 30, 2025, compared to $314,990 thousand in 2024, a decrease of 28.2%[19]. - Basic net income per common share for the three months ended September 30, 2025, was $1.11, down from $1.16 in 2024, a decline of 4.3%[17]. - Net income for the nine months ended September 30, 2025, was $497,083, compared to $525,330 for the same period in 2024, reflecting a decrease of approximately 5.4%[24]. - The company reported comprehensive income of $662,753 for the nine months ended September 30, 2025, compared to $653,746 for the same period in 2024, showing a slight increase of about 1.6%[22]. Assets and Liabilities - Total assets increased to $6,876,443 thousand as of September 30, 2025, up from $6,521,531 thousand at December 31, 2024, representing a growth of 5.4%[15]. - Total liabilities increased to $1,559,157 thousand as of September 30, 2025, from $1,525,435 thousand at December 31, 2024, reflecting a growth of 2.2%[15]. - Total equity rose to $5,317,286 thousand as of September 30, 2025, compared to $4,996,096 thousand at December 31, 2024, an increase of 6.4%[15]. - Cash and cash equivalents at the end of the period on September 30, 2025, were $543,577, down from $673,363 at the end of September 2024, a decrease of about 19.2%[24]. Investment Income and Losses - Net investment income for the three months ended September 30, 2025, was $68,611 thousand, up from $61,056 thousand in 2024, representing an increase of 12.5%[17]. - Net investment income for the nine months ended September 30, 2025, was $197,532, an increase from $177,940 in 2024, indicating a growth of approximately 11%[41]. - For the three months ended September 30, 2025, net investment losses amounted to $2,834,000, compared to losses of $1,243,000 in the same period of 2024, reflecting a significant increase in losses[42]. - For the nine months ended September 30, 2025, net investment losses totaled $13,420,000, compared to $15,640,000 for the same period in 2024, indicating a decrease in losses year-over-year[42]. Insurance and Loss Reserves - Total loss reserves as of September 30, 2025, amounted to $572.1 million, an increase from $524.7 million as of December 31, 2024[105]. - For the nine months ended September 30, 2025, losses and LAE incurred related to insured events of the current accident year were $221 million, compared to $212 million for the same period in 2024[110]. - The gross loss reserves for domestic mortgage insurance increased to $566.9 million as of September 30, 2025, from $520.0 million at the end of 2024[105]. - The company recorded favorable reserve adjustments of $140 million primarily on prior accident year reserves due to improved cure performance of delinquencies[110]. Shareholder Activities - The company repurchased common stock totaling $255,377 during the nine months ended September 30, 2025, compared to $169,321 in the same period of 2024, reflecting an increase of approximately 50.9%[24]. - Cash dividends paid to Genworth were $25.1 million for the three months ended September 30, 2025, and $73.4 million for the nine months ended September 30, 2025[142]. - Total dividends declared and paid per common share for 2025 was $0.605, down from $0.715 in 2024[158]. - During Q3 2025, the company repurchased 2,824,499 shares at an average price of $37.23 per share, compared to 2,096,329 shares at $34.04 per share in Q3 2024[155]. Market Conditions and Performance Metrics - The U.S. mortgage origination market remained slow due to elevated mortgage rates, impacting housing affordability[166]. - The loss ratio for Q3 2025 was 15%, up from 5% in Q3 2024, with a reserve release of $45 million in Q3 2025 compared to $65 million in Q3 2024[172][192]. - The primary persistency rate remained stable at 83% for both Q3 2025 and Q3 2024, indicating strong retention of in-force policies[170]. - New insurance written (NIW) for Q3 2025 was $14.0 billion, representing a 3% increase compared to Q3 2024[170].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-21184 MICROCHIP TECHNOLOGY INCORPORATED (Exact Name of Registrant as Specified in Its Charter) (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-21184 MICROCHIP TECHNOLOGY INCORPORATED $0.001 par value per share (Exact Name of Registrant as Specifi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40815 Definitive Healthcare Corp. (Exact name of registrant as specified in its charter) Delaware 86-3988281 (State or other ...

For Immediate Release Kura Sushi USA Announces Fiscal Fourth Quarter and Fiscal Year 2025 Financial Results Irvine, CA. November 6, 2025 – Kura Sushi USA, Inc. ("Kura Sushi" or the "Company") (NASDAQ: KRUS), a technology- enabled Japanese restaurant concept, today announced financial results for the fiscal fourth quarter and fiscal year ended August 31, 2025. Fiscal Fourth Quarter 2025 Highlights *Adjusted net income, Restaurant-level operating profit and Adjusted EBITDA are non-GAAP measures and are define ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to ________ Commission file number: 001-35593 HOMETRUST BANCSHARES, INC. (Exact name of registrant as specified in its charter) Maryland 45-5055422 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission file number 001-39510 STEPSTONE GROUP INC. (Exact name of Registrant as specified in its charter) D ...

Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 Exhibit 99.1 vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousan ...